AllianceBernstein’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

AllianceBernstein’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-98,894	Closed	-$13M	–	3362
2020 Q4	$13M	Buy	98,894 +79,594	+412%	+$7.03M	0.01%	1012
2020 Q3	$975K	Buy	19,300 +300	+2%	+$13.5K	﹤0.01%	2196
2020 Q2	$906K	Buy	19,000 +3,400	+22%	+$158K	﹤0.01%	2257
2020 Q1	$764K	Sell	15,600 -1,100	-7%	-$56K	﹤0.01%	2156
2019 Q4	$958K	Sell	16,700 -700	-4%	-$34.7K	﹤0.01%	2298
2019 Q3	$626K	Sell	17,400 -1,600	-8%	-$62.5K	﹤0.01%	2452
2019 Q2	$591K	Buy	19,000 +6,700	+54%	+$182K	﹤0.01%	2533
2019 Q1	$288K	Buy	+12,300	New	+$197K	﹤0.01%	2777

AllianceBernstein's EIDX Position: Q1 2021 in Review

AllianceBernstein sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 98,894 shares — an estimated $13M sold.

AllianceBernstein first reported a position in EIDX in Q1 2019 and held it in 8 quarters. The position peaked at $13M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

AllianceBernstein reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
AllianceBernstein sold 98,894 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $13M.
AllianceBernstein first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
AllianceBernstein's Eidos Therapeutics, Inc. Common Stock position peaked at $13M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on AllianceBernstein's 13F filing for Q1 2021, filed 6 May 2021.